The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
Glioblastoma multiforme: Pathogenesis and treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–265 of 265
Spence, A. M., Peterson, R. A., Scharnhorst, J., Silbergeld, D. L., & Rostomily, R. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000040837.68411.97 · Cited by 61
Franceschi, E., Stupp, R., van den Bent, M. J., van Herpen, C., Laigle–Donadey, F., Gorlia, T., Hegi, M. E., Lhermitte, B., Strauss, L. C., Allgeier, A., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos256 · Cited by 61
Wick, W., Steinbach, J. P., Platten, M., Hartmann, C. J., Wenz, F. K., von Deimling, A., Shei, P., MOREAU, V., Stoffregen, C., & Combs, S. E. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not100 · Cited by 61
Sarangi, A., Valadez, J. G., Rush, S. Z., Abel, T. W., Thompson, R. C., & Cooper, M. K. (2009) · Oncogene · doi:10.1038/onc.2009.208 · Cited by 60
Somatic Mutations of PIK3R1 Promote Gliomagenesis
Quayle, S. N., Lee, J. Y., Cheung, L. W. T., Ding, L., Wiedemeyer, R., Dewan, R. W., Huang-Hobbs, E., Zhuang, L., Wilson, R. K., Ligon, K. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049466 · Cited by 59
Robins, H. I., Won, M., Seiferheld, W. F., Schultz, C. J., Choucair, A. K., Brachman, D. G., Demas, W. F., & Mehta, M. P. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000311 · Cited by 59
The efficacy of temozolomide for recurrent glioblastoma multiforme
Chen, C., Xu, T., Lu, Y., Chen, J., & Wu, S. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03778.x · Cited by 58
Brain Cancer Stem Cells: Current Status on Glioblastoma Multiforme
Facchino, S., Abdouh, M., & Bernier, G. (2011) · Cancers · doi:10.3390/cancers3021777 · Cited by 57
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Asklund, T., Kvarnbrink, S., Holmlund, C., Wibom, C., Bergenheim, T. A., Henriksson, R., & Hedman, H. (2012) · PubMed · Cited by 56
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma
Hiddingh, L., Tannous, B. A., Teng, J., Tops, B. B. J., Jeuken, J. W. M., Hulleman, E., Boots‐Sprenger, S., Vandertop, W. P., Noske, D. P., Kaspers, G. J. L., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1620 · Cited by 55
Bhat, N. R., & Fan, F. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02953-0 · Cited by 54
Drappatz, J., Wong, E. T., Schiff, D., Kesari, S., Batchelor, T. T., Doherty, L. M., LaFrankie, D. C., Ramakrishna, N. R., Weiss, S. E., Smith, S. T., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.03.046 · Cited by 54
An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Guessous, F., Zhang, Y., diPierro, C. G., Marcinkiewicz, L., Sarkaria, J. N., Schiff, D., Buchanan, S. G., & Abounader, R. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009010028 · Cited by 54
Cheng, H., Yue, W., Xie, C., Zhang, R., Hu, S., & Wang, Z. (2013) · Tumor Biology · doi:10.1007/s13277-013-0934-5 · Cited by 53
Höring, E., Podlech, O., Silkenstedt, B., Rota, I. A., Adamopoulou, E., & Naumann, U. (2013) · PubMed · Cited by 52
The Effects of Histone Deacetylase Inhibitors on Glioblastoma-Derived Stem Cells
Alvarez, A. A., Field, M., Bushnev, S., Longo, M. S., & Sugaya, K. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0329-0 · Cited by 52
Kast, R. E., & Halatsch, M. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.04.005 · Cited by 50
McCarty, M. F. (1997) · Medical Hypotheses · doi:10.1016/s0306-9877(97)90217-6 · Cited by 49
Nordenberg (2010) · International Journal of Oncology · doi:10.3892/ijo_00000756 · Cited by 49
Buchanan, I. M., Scott, T., Tandle, A. T., Burgan, W. E., Burgess, T. L., Tofilon, P. J., & Camphausen, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01122.x · Cited by 48
Gini, B., Zanca, C., Guo, D., Matsutani, T., Masui, K., Ikegami, S., Yang, H., Nathanson, D. A., Villa, G. R., Shackelford, D. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0527 · Cited by 48
Mason, W. P., Bélanger, K., Nicholas, G. A., Vallières, I., Mathieu, D., Kavan, P., Desjardins, A., Omuro, A. M. P., & Reymond, D. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0747-6 · Cited by 47
de la Peña, L., Burgan, W. E., Carter, D. J., Hollingshead, M. G., Satyamitra, M. M., Camphausen, K. A., & Tofilon, P. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0091 · Cited by 47
Brain Distribution of Cediranib Is Limited by Active Efflux at the Blood-Brain Barrier
Wang, T., Agarwal, S., & Elmquist, W. F. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190488 · Cited by 46
The Role of BCNU Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma
Nagpal, S. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.01.004 · Cited by 46
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K. B., Sathornsumetee, S., Threatt, S., Sampson, J. H., Herndon, J. E., Sykes, A. D., McSherry, F., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0848-x · Cited by 45
Ferruzzi, P., Mennillo, F., Rosa, A. D., Giordano, C., Rossi, M., Benedetti, G., Magrini, R., Mohr, G. L. P., Miragliotta, V., Magnoni, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27349 · Cited by 45
Vitespen: A Preclinical and Clinical Review
Wood, C. G., & Mulders, P. (2009) · Future Oncology · doi:10.2217/fon.09.46 · Cited by 45
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
Li, Y., Guessous, F., diPierro, C. G., Zhang, Y., Mudrick, T., Fuller, L., Johnson, E. K., Marcinkiewicz, L., Engelhardt, M., Kefas, B. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0627 · Cited by 44
Ribot, E. J., Bouzier‐Sore, A., Bouchaud, V., Miraux, S., Delville, M., Franconi, J., & Voisin, P. J. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701060 · Cited by 43
Efficacy of rapamycin against glioblastoma cancer stem cells
Mendiburu‐Eliçabe, M., Gil-Ranedo, J., & Izquierdo, M. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1109-y · Cited by 42
Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors
Mitchell, D. A., & Sampson, J. H. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.003 · Cited by 41
Lentiviral transduction of microglial cells
Balcaitis, S. D., Weinstein, J. R., Li, S., Chamberlain, J. S., & Möller, T. (2004) · Glia · doi:10.1002/glia.20146 · Cited by 41
Yelskaya, Z., Carrillo, V., Dubisz, E., Gulzar, H., Morgan, D., & Mahajan, S. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064588 · Cited by 40
Targeting ErbB Receptors in High-Grade Glioma
Berezowska, S., & Schlegel, J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797249233 · Cited by 40
Vlachostergios, P. J., Hatzidaki, E., Befani, C. D., Liakos, P., & Papandreou, C. N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9968-1 · Cited by 39
Yiin, J., Hu, B., Schornack, P. A., Sengar, R. S., Liu, K.-W., Feng, H., Lieberman, F. S., Chiou, S., Sarkaria, J. N., Wiener, E. C., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0953 · Cited by 39
Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
Onishi, M., Kurozumi, K., Ichikawa, T., & Date, I. (2013) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra2013-0200 · Cited by 38
Yust‐Katz, S., Liu, D., Yuan, Y., Liu, V., Kang, S., Groves, M. D., Puduvalli, V. K., Levin, V. A., Conrad, C. A., Colman, H., et al. (2013) · Cancer · doi:10.1002/cncr.28031 · Cited by 36
Coupling to a glioblastoma-directed antibody potentiates antitumor activity of curcumin
Langone, P., Debata, P. R., Inigo, J. D. R., Dolai, S., Mukherjee, S., Halat, P., Mastroianni, K., Curcio, G. M., Castellanos, M. R., Raja, K. S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28555 · Cited by 36
Etoposide improves survival in high-grade glioma: a meta-analysis.
Leonard, A. K., & Wolff, J. E. A. (2013) · PubMed · Cited by 36
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme
Fadul, C. E., Kingman, L. S., Meyer, L. P., Cole, B. F., Eskey, C. J., Rhodes, C. H., Roberts, D. W., Newton, H. B., & Pipas, J. M. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9655-9 · Cited by 36
Vaccine Strategies for Glioblastoma: Progress and Future Directions
Jackson, C. M., Ruzevick, J., Brem, H., & Lim, M. K. (2013) · Immunotherapy · doi:10.2217/imt.12.155 · Cited by 35
Lin, J., Zhang, X., Yang, J., Ye, Y.-B., & Luo, S.-Q. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.10.006 · Cited by 35
Wang, Y., Pan, L., Sheng, X., Chen, S., & Dai, J. (2014) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12166 · Cited by 34
Floyd, D. H., Kefas, B. A., Seleverstov, O., Mykhaylyk, O. M., Dominguez, C. L., Comeau, L., Plank, C., & Purow, B. W. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos157 · Cited by 31
Notch Signaling and Brain Tumors
Stockhausen, M., Kristoffersen, K., & Poulsen, H. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_22 · Cited by 30
Gilbert, M. R., Gaupp, P., Liu, V., Conrad, C., Colman, H., Groves, M. D., Puduvalli, V. K., Levin, V. A., Hsu, S., Horowitz, J. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.1556 · Cited by 28
Therapeutic targeting of EGFR in malignant gliomas
Ye, F., Gao, Q., & Cai, M. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003598948 · Cited by 27
Karavasilis, V., Kotoula, V., Pentheroudakis, G. E., Televantou, D., Lambaki, S., Chrisafi, S., Bobos, M., & Fountzilas, G. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6812-z · Cited by 26
Fields, E. C., Damek, D., Gaspar, L. E., Liu, A. K., Kavanagh, B. D., Waziri, A. E., Lillehei, K. O., & Chen, C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.008 · Cited by 25
Greenall, S. A., Donoghue, J. F., Gottardo, N. G., Johns, T. G., & Adams, T. E. (2014) · Oncogene · doi:10.1038/onc.2014.106 · Cited by 24
Heat shock protein–peptide complex in the treatment of glioblastoma
See, A. P., Pradilla, G., Yang, I., Han, S. J., Parsa, A. T., & Lim, M. K. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.49 · Cited by 24
Johns, T. G., McKay, M. J., Cvrljevic, A. N., Gan, H. K., Taylor, C., Xu, H., Smyth, F. E., & Scott, A. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.027 · Cited by 23
2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies
Ahluwalia, M. S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.227 · Cited by 23
Kast, R. E. (2010) · Central European Neurosurgery · doi:10.1055/s-0029-1242756 · Cited by 22
Du, W., Zhou, J., Wang, D., Gong, K., & Zhang, Q. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-60 · Cited by 21
Gruber, M. L., Raza, S., Gruber, D., & Narayana, A. S. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2017 · Cited by 21
Reardon, D. A., Wen, P. Y., Yung, W. K. A., Berk, L., Narasimhan, N. I., Turner, C. D., Clackson, T. P., Rivera, V. M., & Vogelbaum, M. A. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1773-y · Cited by 20
Majumdar, K., Radotra, B. D., Vasishta, R. K., & Pathak, A. (2009) · Surgical Neurology · doi:10.1016/j.surneu.2008.10.001 · Cited by 16
Tamura, N., Hirano, K., Kishino, K., Hashimoto, K., Amano, O., Shimada, J., & Sakagami, H. (2012) · PubMed · Cited by 16
Lai, A., Nghiemphu, P. L., Green, R. M., Spier, L., Peak, S., Phuphanich, S., Fehrenbacher, L., Kolevska, T., Polikoff, J. A., & Cloughesy, T. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2000 · Cited by 15
Sharma, V., Shaheen, S. S., Dixit, D., & Sen, E. (2011) · Inflammation · doi:10.1007/s10753-011-9340-6 · Cited by 12
Liang, Q., Mo, Z.-Y., Wang, P., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0122-5 · Cited by 12
Longo, S. L., Padalino, D. J., McGillis, S. L. B., Petersen, K., Schirok, H., Politz, O., Canute, G. W., & Post, D. E. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9784-4 · Cited by 9
Cited by
Glioblastoma: Overview of Disease and Treatment
Davis, M. (2016) · Clinical Journal of Oncology Nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,205
Current and future strategies for treatment of glioma
Bush, N. A. O., Chang, S. M., & Berger, M. S. (2017) · Neurosurgical Review · doi:10.1007/s10143-016-0709-8 · Cited by 577
Israel, L. L., Galstyan, A., Holler, E., & Ljubimova, J. Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.009 · Cited by 337
Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153550 · Cited by 330
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Kramer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 320
Metadata
- Authors
- Alifieris, C., & Trafalis, D. T.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 152
- Pages
- 63-82
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1998941426
- Cited by
- 820
- References
- 265
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.